Inhibition of topoisomerase IIα and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials

Molecular Cancer Therapeutics

Volumn 6, Issue 5, 2007, Pages 1501-1508

  Guo, Lei ^a,b   Liu, Xiaojun ^a   Nishikawa, Kiyohiro ^c   Plunkett, William ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NIPPON KAYAKU CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; BENZO[C]PHENANTHRIDINE DERIVATIVE; CAMPTOTHECIN; CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOUBLE STRANDED DNA; ETOPOSIDE; HISTONE H2AX; NK 314; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; TOPOISOMERASE IIALPHA; UNCLASSIFIED DRUG; 7-HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; DRUG DERIVATIVE; ENZYME INHIBITOR; H2AFX PROTEIN, HUMAN; HISTONE; NK314; PHENANTHRENE DERIVATIVE; PHENANTHRIDINE DERIVATIVE; STAUROSPORINE; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL LINE; CHROMOSOME ABERRATION; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; DNA SUPERCOILING; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SENSITIVITY ANALYSIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; METHODOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CLINICAL TRIALS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; G2 PHASE; HISTONES; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; PHENANTHRENES; PHENANTHRIDINES; PHOSPHORYLATION; STAUROSPORINE;

EID: 34250782722     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0780     Document Type: Article

References (40)

1. Ishii H, Ishikawa T. [Chemistry of benzo[c]phenanthridine alkaloids having antineoplastic activity (author's transl)]. Yakugaku Zasshi 1981;101:663-87.
2. Messmer WM, Tin-Wa M, Fong HH, et al. Fagaronine, a new tumor inhibitor isolated from Fagara zanthoxyloides Lam. (Rutaceae). J Pharm Sci 1972;61:1858-9.
3. Cheng CC, Engle RR, Hodgson JR, et al. Absence of mutagenicity of coralyne and related antileukemic agents: structural comparison with the potent carcinogen 7,12-dimethylbenz[a]anthracene. J Pharm Sci 1977;66:1781-3.
4. Fleury F, Sukhanova A, Ianoul A, et al. Molecular determinants of site-specific inhibition of human DNA topoisomerase I by fagaronine and ethoxidine. Relation to DNA binding. J Biol Chem 2000;275:3501-9.
5. Larsen AK, Grondard L, Couprie J, et al. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem Pharmacol 1993;46:1403-12.
6. Wang LK, Johnson RK, Hecht SM. Inhibition of topoisomerase I function by nitidine and fagaronine. Chem Res Toxicol 1993;6:813-8.
7. Nakanishi T, Suzuki M, Saimoto A, Kabasawa T. Structural considerations of NK109, an antitumor benzo[c]phenanthridine alkaloid. J Nat Prod 1999;62:864-7.
8. Fukuda M, Inomata M, Nishio K, et al. A topoisomerase II inhibitor, NK109, induces DNA single- and double-strand breaks and apoptosis. Jpn J Cancer Res 1996;87:1086-91.
9. Kanzawa F, Nishio K, Ishida T, et al. Antitumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8- methoxybenzo[c]phenanthridinium hydrogen sulphate dihydrate (NK109), against several drug-resistant human tumour cell lines. Br J Cancer 1997;76:571-81.
10. Nakanishi T, Masuda A, Suwa M, et al. Synthesis of derivatives of NK109, 7-OH benzo[c]phenanthridine alkaloid, and evaluation of their cytotoxicities and reduction-resistant properties. Bioorg Med Chem Lett 2000;10:2321-3.
11. Okamoto K, Seno C, Onda T, Toyoda E, Nishikawa K. Rapid DNA breakage induced by a novel antitumor agent, NK314 [abstract #1368]. Proc Am Assoc Cancer Res 2005;46:319-b.
12. Bugg BY, Danks MK, Beck WT, Suttle DP. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci U S A 1991;88:7654-8.
13. Kapoor R, Slade DL, Fujimori A, Pommier Y, Harker WG. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol Res 1995;7:83-95.
14. Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res 1995;55:1339-46.
15. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
16. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 2000;275:9390-5.
17. Graves PR, Yu L, Schwarz JK, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000;275:5600-5.
18. Sampath D, Cortes J, Estrov Z, et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 2006;107:2517-24.
19. Hotte SJ, Oza A, Winquist EW, et al. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol 2006;17:334-40.
20. Kortmansky J, Shah MA, Kaubisch A, et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors. J Clin Oncol 2005;23:1875-84.
21. 2 arrest induced by 2′-C-cyano-2′-deoxy-1-β-D-arabino- pentofuranosylcytosine and consequences of checkpoint abrogation. Cancer Res 2005;65:6874-81.
22. Makhey D, Gatto B, Yu C, et al. Coralyne and related compounds as mammalian topoisomerase I and topoisomerase II poisons. Bioorg Med Chem 1996;4:781-91.
23. Gantchev TG, Hunting DJ. The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex. Mol Pharmacol 1998;53:422-8.
24. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 1988;27:8861-9.
25. Danks MK, Yalowich JC, Beck WT. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 1987;47:1297-301.
26. Chen M, Beck WT. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase IIα, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res 1993;53:5946-53.
27. Vogt A, Tamewitz A, Skoko J, et al. The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J Biol Chem 2005;280:19078-86.
28. Kagaya S, Toyoda E, Tokunaka K, et al. NK314, a novel antitumor agent, induces rapid double-strand DNA breaks by specific inhibition of topoisomerase IIα [abstract #5525]. Proc Am Assoc Cancer Res 2006;47:1299-a.
29. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001;276:42462-7.
30. Ward IM, Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem 2001;276:47759-62.
31. 1-phase cells. Radiat Res 2003;159:759-67.
32. Furuta T, Takemura H, Liao ZY, et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 2003;278:20303-12.
33. Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 1990;10:5502-9.
34. Duthu A, Debuire B, Romano J, et al. p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas. Oncogene 1992;7:2161-7.
35. Law JC, Ritke MK, Yalowich JC, Leder GH, Ferrell RE. Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leuk Res 1993;17:1045-50.
36. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci U S A 1985;82:790-4.
37. 2 arrest after DNA damage. Science 1998;282:1497-501.
38. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-9.
39. Kalwinsky DK, Look AT, Ducore J, Fridland A. Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Res 1983;43:1592-7.
40. Barlogie B, Drewinko B, Johnston DA, Freireich EJ. The effect of Adriamycin on the cell cycle traverse of a human lymphoid cell line. Cancer Res 1976;36:1975-9.